Abstract:Chao Hong, 1, 2, &ast Anni Wang, 1, &ast Jiaxuan Xia, 1 Jianming Liang, 1, 3 Ying Zhu, 1 Dan Wang, 1, 4 Huaxing Zhan, 4 Chunbo Feng, 5 Xinnan Jiang, 5 Junjie Pan, 6 Jianxin Wang 1, 7 1 Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai, 201203, People's Republic of China; 2 School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China; 3 Institute of Tropical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, 510006, People's Republic of China; 4 Xiamen Ginposome Pharmaceutical Co., Ltd, Xiamen, 361026, People's Republic of China; 5 R&D Center, Shanghai Jahwa United Co., Ltd, Shanghai, 200082, People's Republic of China; 6 Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, 200040, People's Republic of China; 7 Institute of Integrated Chinese and Western Medicine, Fudan University, Shanghai, 200040, People's Republic of China &astThese authors contributed equally to this work Correspondence: Junjie Pan; Jianxin Wang, Email ; Background: Most solid tumors are not diagnosed and treated until the advanced stage, in which tumors have shaped mature self-protective power, leading to off-target drugs and nanomedicines. In the present studies, we established a more realistic large tumor model to test the antitumor activity of a multifunctional ginsenoside Rh2-based liposome system (Rh2-lipo) on advanced breast cancer. Methods: Both cholesterol and PEG were substituted by Rh2 to prepare the Rh2-lipo using ethanol-water system and characterized. The effects of Rh2-lipo on cell uptake, penetration of the tumor spheroid, cytotoxicity assay was investigated with 4T1 breast cancer cells and L929 fibroblast cells. The 4T1 orthotopic-bearing large tumor model was established to study the targeting effect of Rh2-lipo and inhibitory effect of paclitaxel loaded Rh2-lipo (PTX-Rh2-lipo) on advanced breast tumors. Results: Rh2-lipo exhibit many advantages that address the limitations of current liposome formulations against large tumors, such as enhanced uptake in TAFs and tumor cells, high targeting and penetration capacity, cytotoxicity against TAFs, normalization of the vessel network, and depletion of stromal collagen. In in vivo study, PTX-Rh2-lipo effectively inhibiting the growth of advanced breast tumors and outperformed most reported PTX formulations, including Lipusu ® and Abraxane ® . Conclusion: Rh2-lipo have improved drug delivery efficiency and antitumor efficacy in advanced breast cancer, which offers a novel promising platform for advanced tumor therapy. Keywords: nanomedicine, tumor microenvironment, chemotherapy, tumor-associated fibroblast Graphical Cancer remains a highly fatal disease in the world. The past three decades have witnessed a great expansion of research in the field of cancer nanomedicine. Various nanoparticles that include lipid-based nanoparticles, polymeric nanoparticles, and inorganic nanoparticles have been developed for targeted delivery of therapeutic nucleic acids, 1 chemotherapeutic agents, 2 or immunotherapeutic agents to tumors. 3 The advantage of using nanomedicines to treat cancer is that they can effectively target and deliver drugs to the tumor site, 4 reducing side effects and improving treatment efficiency. In addition, nanomedicines have a controlled release function, allowing drugs to be slowly released at the tumor site, reducing the frequency of dosing, and improving patient compliance. 5 However, there is a large body of literature describing different nanoparticles as potential cancer therapies, yet only a handful has been US Food and Drug Administration (FDA) approved. 6 The tumor microenvironment (TME) is well known for its important role in cancer development and metastasis 7–9 Various cells in the TME, especially stromal cells, including tumor-associated fibroblasts (TAFs), collagen, and endothelial cells, form a physical barrier within tumors to inhibit penetration of therapeutic nanoparticles and secrete growth-inducing cytokines and growth factors to facilitate the survival of tumor cells, which finally results in the resistance of nanochemotherapy 7,9 Evidence has shown that in the early stages of tumor growth, the composite of the TME is much simpler and far from shaping self-protective mechanisms. 10 When tumor grow -Abstract Truncated-

Enhanced anti-glioma activity of annonaceous acetogenins based on a novel liposomal co-delivery system with ginsenoside Rh2

One Stone Four Birds: A Novel Liposomal Delivery System Multi-functionalized with Ginsenoside Rh2 for Tumor Targeting Therapy

Rg3-lipo biomimetic delivery of paclitaxel enhances targeting of tumors and myeloid-derived suppressor cells

Multifunctional Ginsenoside Rg3-based Liposomes for Glioma Targeting Therapy.

Bioinspired ginsenoside Rg3 PLGA nanoparticles coated with tumor-derived microvesicles to improve chemotherapy efficacy and alleviating toxicity

Poly(lactic acid hydroxyacetic acid)-poly(ethylene glycol)-modified ginsenoside Rg3 nanomedicine enhances anti-tumor effect in hepatocellular carcinoma

A comparative study of PEO-PBO content on the targeting and anti-glioma activity of annonaceous acetogenins-loaded nanomicelles

Novel ginsenoside-based multifunctional liposomal delivery system for combination therapy of gastric cancer

Enhancement of the antitumor effect of cisplatin and ginsenoside Rg3 by encapsulation in polylactic-co-glycolic acid nanoparticles

Ginsenoside Rb1 stabilized and paclitaxel / protopanaxadiol co-loaded nanoparticles for synergistic treatment of breast tumor

Targeted delivery of ginsenoside compound K using TPGS/PEG-PCL mixed micelles for effective treatment of lung cancer

Ginsenoside Rh2-Based Multifunctional Liposomes for Advanced Breast Cancer Therapy

Enhancing anti-tumor therapy with agmatine-cholesterol conjugate liposomes: in vitro and in vivo evidence

RGD-modified Liposomes Enhance Efficiency of Aclacinomycin A Delivery: Evaluation of Their Effect in Lung Cancer.

Enhanced Antitumor Efficacy of Arginine Modified Amphiphilic Nanoparticles Co-Delivering Doxorubicin and Isur-Pdna Via the Multiple Synergistic Effect.

Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy.

Improving aqueous solubility and antitumor effects by nanosized gambogic acid-mPEG₂₀₀₀ micelles.

Antitumor activities of novel glycyrrhetinic acid-modified lipogel hybrid system in vitro

Angiopep-2 and Activatable Cell-Penetrating Peptide Dual-Functionalized Nanoparticles for Systemic Glioma-Targeting Delivery.

Rgd-Based Strategies for Improving Antitumor Activity of Paclitaxel-Loaded Liposomes in Nude Mice Xenografted with Human Ovarian Cancer

Enhanced antitumor efficacy by d-glucosamine-functionalized and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) polymer nanoparticles.